PDS0203 is a novel investigational COVID-19 vaccine that generates broad and robust antibody and T cell responses that provide durable protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). PDS0203 is given as a single dose by intramuscular injection and generates robust and durable protection against COVID-19 in preclinical studies.
In January of 2020 the world saw the emergence of the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared COVID-19 a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread.
PDS0203 is currently in pre-clinical development.